Another of Teva’s businesses could be up for grabs—and this time, it’s oncology, the company confirmed Wednesday.
A big chunk of Brazilian drugmaker Hypermarcas may be up for grabs—and Big Pharma is all over it.
Scientific progress is leading to effective—but sometimes expensive—new treatments. Learn how value-based contracting could be the solution to pay for these…
Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.
The U.S. Treasury is set to review recent tax rules—and that means the crackdown that ended pharma’s tax-inversion-mania could be in for a change.
Teva contends that Mexican generics buy Rimsa sold defective, illegal products and lied about it. But a new memo from Mexico’s drug regulator doesn't help…
German drugmaker Stada has announced plans to sell itself for €5.32 billion ($5.63 billion) shortly after weighing a $3.7 billion private equity takeout.
After an M&A downturn in 2016, industry watchers have been hoping for a resurgence. But so far this year, deal activity has slowed even more.
Teva execs may have zeroed in on their first big revamp move since CEO Erez Vigodman's sudden exit.
Embattled Valeant has promised its investors $8 billion in asset sales—but as the company’s latest deal struggles continue to demonstrate, getting there may…